The Weekly Roundup: January 26-30

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Multi-Ingredient Topical Treatment Significantly Improves Wrinkles and Skin Thickness in Patients with "Ozempic Face"

Discover how a new topical cream effectively improves skin volume and elasticity in patients experiencing rapid weight loss.

Phase 2 Trial Suggests Disease-Modifying Role for Bitopertin in EPP

Bitopertin shows promise as a disease-modifying therapy for erythropoietic protoporphyria, significantly reducing PPIX levels and improving patient outcomes.

FAQtual Insights: Top Career Tips for Early-Career NPs and PAs

Discover essential career insights for early-career NP/PAs in dermatology, focusing on skill mastery, mentorship, and professional growth strategies.

Modern, Multi-Modal Approaches to Repigmentation in Patients with Vitiligo

Christopher Bunick, MD, PhD, led a vital discussion on innovative vitiligo treatments, emphasizing combination therapies and psychosocial support for effective management.

Obagi Medical and Alpha Aesthetic Partners Announce Collaboration on ALOHA Program

Obagi and Alpha Aesthetic Partners will collaborate on the ALOHA Program, enhancing real-world evidence for the innovative saypha MagIQ hyaluronic acid filler.

Dual ITK/JAK3 Inhibition Shows Strong Preclinical Activity in Severe Alopecia Areata

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.

Jennelle Daly, MPAS, PA-C, on Bridging the Gap in Winter UV Education and Patient Adherence

Jennelle Daly, MPAS, PA-C, reveals essential winter sunscreen insights, emphasizing UVA risks and patient education for effective photoprotection against melanoma.

Beyond Weight Loss: Clinical Perspectives on GLP-1s for Inflammatory Dermatoses

Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.

Litifilimab Shows Early Skin Benefits in CLE

Litifilimab shows significant efficacy in improving skin outcomes for CLE, as demonstrated in the phase 2 LILAC study.

Q&A with Karen McGuire, PhD: How TolaSure Aims to Redefine the Standard of Care for EBS

Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.

Phase 2b Analysis Shows Consistent Vitiligo Repigmentation With Ritlecitinib

Ritlecitinib shows promising facial repigmentation in vitiligo patients, with consistent efficacy across diverse demographics in a phase 2b study.

Journal Digest: January 28, 2026

This review of the latest vitiligo studies includes insights on the efficacy of ritlecitinib, the risk of herpes zoster, oxidative stress in red blood cells for this patient population, and more.

FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus

The FDA’s decision was based on litifilimab’s phase 2 skin disease activity data.

On the Horizon: Innovations in the Acne Treatment Pipeline

Innovative acne treatments emerge, including sponge-derived therapies and microbiome strategies, promising a brighter future for patients.

FAQtual Insights: Safe Approaches to Off Label Prescribing

Explore the nuances of off-label dermatology therapies, emphasizing evidence-based practices, patient communication, and ethical considerations for optimal care.

Beyond UV: The Critical Role of HEV Protection and Post-Procedural Care

Explore the importance of HEV blue light protection, especially post-procedures, and discover effective patient strategies for managing melasma and skin health.

Bill Andriopoulos, PhD: Inside the PEARL Technology and Phase 3 Results of Relfydess

Discover insights from Bill Andriopoulos, PhD, on Relfydess, a groundbreaking neuromodulator utilizing PEARL Technology for enhanced efficacy and safety.

Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo

James Del Rosso, DO, discusses innovative therapies for chronic hand eczema (CHE), chronic spontaneous urticaria (CSU), and vitiligo.

Patient Perspectives Reveal the Hidden Burden of Drainage in HS

Explore the nuanced experiences of drainage in hidradenitis suppurativa (HS), revealing its profound physical and psychological impacts on patients' lives.

Interview Intersection: Expert Interviews From January 2026

Dermatology Times is recapping our exclusive expert interviews from the month of January.

How Galderma is Modernizing Aesthetic Trends and Patient Outcomes Around the World

Galderma's Bill Andriopoulos, PhD, discusses Dysport's real-world success and evolving trends in aesthetic injectables, emphasizing patient satisfaction and innovative treatments.

Dermatology Times January 2026 Print Recap

Learn more about the in-depth topics covered in the January 2026 print issue of Dermatology Times.

Galderma Prioritizes Menopause-Related Skin Health with New Data at IMCAS 2026

Galderma addresses menopause-related skin changes at IMCAS 2026, revealing survey insights and committing to inclusive clinical trials for better patient solutions.

Phase 2 TYK2 Inhibition Shows Promise in AD

A phase 2 trial reveals soficitinib's potential to significantly improve symptoms and quality of life in patients with moderate to severe AD.

Top 5 Articles of the Month: January 2026

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

The Growing Role of Integrative Medicine in Aesthetic Dermatology

Jennelle Daly, PA-C, explores the integration of aesthetic dermatology and wellness, emphasizing holistic approaches for optimal skin health and patient outcomes.

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

Icotrokinra emerges as a groundbreaking oral treatment for moderate-to-severe psoriasis, showing superior efficacy compared to existing therapies at Maui Derm 2026.

Dermatology Times January 2026 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of January.

Kyowa Kirin Takes Full Control of Rocatinlimab Program

Kyowa Kirin takes full control of rocatinlimab, aiming to address unmet needs in atopic dermatitis while ensuring continuity in clinical trials.